Intent to Sole Source - BD Bioscience Reagents

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH

Contract Value

Not provided

Codes & Classification
Solicitation Number

-

NAICS

334516 - Analytical Laboratory Instrument Manufacturing

Classification Code

6550

Additional Details
Set Aside

NONE

Place of Performance

Bethesda, Maryland, UNITED STATES

SourceSAM
Documents3
The National Institutes of Health (NIH), Office of Logistics and Acquisitions, has issued a Special Notice indicating its intent to negotiate a sole source procurement with BD Biosciences for the supply of specialized reagents and consumables. This acquisition is not a request for proposal; rather, it serves as a public notification of the agency’s intent to procure these items on an other than full and open competition basis, in accordance with statutory authority 41 U.S.C. 1901 (a)(1) as implemented by FAR 13.106-1. The justification for this approach is that only BD Biosciences can provide the required supplies to meet the agency’s needs. The scope of this procurement encompasses the as-needed purchase of monoclonal antibodies, assay quality controls, buffers, sheath fluids, and disposable components essential for clinical patient-care quality control flow cytometry assays. These assays are performed using the FACSLyris flow cytometer, a BD Biosciences instrument, within the Center of Cellular Engineering (CCE), Department of Transfusion Medicine. The CCE is an AABB-accredited cellular therapy laboratory whose mission is to support NIH’s intramural clinical trials by manufacturing clinical therapies from cells collected from NIH Clinical Center patients and healthy donors. These therapies are used in the treatment of cancer, hematological malignancies, marrow failure, congenital immune disorders, and autoimmune diseases, and are produced in compliance with FDA manufacturing guidelines. Each use of the FACSLyris instrument requires fresh, sterile, single-use vials of monoclonal antibodies (one to four vials per procedure), along with other consumables. The reagents and components supplied by BD Biosciences are validated for use in regulated clinical laboratory environments and are integral to immunophenotyping, in-process testing, and lot release flow cytometry assays. The reliability and compatibility of these products with the existing BD Biosciences instrumentation are critical to maintaining the quality and regulatory compliance of the laboratory’s operations. The place of performance for this requirement is Bethesda, Maryland. The applicable NAICS code is 334516 (Analytical Laboratory Instrument Manufacturing), and the Product Service Code is 6550. There are no set-aside restrictions associated with this procurement. Interested parties who believe they can provide the required supplies are invited to submit a capability statement by 11:00 AM Eastern Standard Time on March 7, 2026, referencing NOI-CC-26-002633, to [email protected]. All responses received by the deadline will be considered; however, the final determination to compete this requirement remains at the sole discretion of the Government. For further details, the official notice and supporting documents can be accessed via the SAM.gov opportunity ID 01e5cf545e6c4c51a0dc85b5f2a7b6d3. Contracting Entity: National Institutes of Health Department of Health and Human Services Bethesda, Maryland, USA Contact: [email protected] This notice is active as of February 25, 2026, with a response deadline of March 7, 2026.